R115777 in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant tumors deemed to be incurable or refractory to therapy
• * Advanced, recurrent, or metastatic disease
• Previously treated with at least 1 chemotherapy regimen
• Brain metastases allowed if asymptomatic and controlled (e.g., after prior surgical resection or radiotherapy/radiosurgery) and not on steroids or anticonvulsants
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 3,500/mm3
• Absolute granulocyte count at least 1,500/mm3
• Platelet count at least 75,000/mm3
• Hepatic:
• Bilirubin no greater than 2.5 times upper limit of normal (ULN)
• SGOT no greater than 2.5 times ULN
• Renal:
• Creatinine clearance at least 60 mL/min OR
• Creatinine no greater than 1.6 mg/dL
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent biologic therapy
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea)
• Endocrine therapy:
• See Disease Characteristics
• No concurrent hormonal therapy
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and recovered
• No prior radiotherapy to a field containing a measurable target lesion unless there is evidence of progression or a new lesion is present
• No concurrent radiotherapy to measurable lesions
• Surgery:
• See Disease Characteristics
• At least 3 weeks since prior major surgery and recovered
• Other:
• At least 2 weeks since prior proton pump inhibitors (e.g., omeprazole)
• Concurrent H2 blockers (e.g., cimetidine or related drugs) or antacids are allowed if there is an interval of at least 2 hours between H2 blocker/antacid intake and R115777 dosing